C. Michael Gibson and George Dangas discuss edoxaban vs vitamin K antagonists after TAVI in patients with atrial fibrillation.

C. Michael Gibson and Bertam Pitt discuss the role of finerenone in patients with chronic kidney disease and type 2 diabetes.

C. Michael Gibson and Dhanunjaya Lakkireddy discuss device success and thrombus risk in Amulet versus Watchman for LAA closure.

C. Michael Gibson and Timothy Henry discuss key updates to the SCAI SHOCK classifications.

C. Michael Gibson and Renato Lopes discuss extended DOAC prophylaxis in medically ill, hospitalized patients with COVID-19.

C. Michael Gibson and Nicholas Curzen discuss whether routine pressure-wire assessment influences the use of coronary angiography for diagnosing chest pain.

C. Michael Gibson and David Cohen discuss cost implications of this TAVI versus SAVR randomized trial.

C. Michael Gibson and Ole Fröbert discuss the potential for influenza vaccination in post-MI patients.

C. Michael Gibson and Wan Azman Wan Ahmad discuss a sirolimus-versus a paclitaxel-coated balloon in de novo coronary lesions.

C. Michael Gibson and Stefan Anker discuss the effects of empagliflozin on CV death and HF hospitalizations in patients with HFpEF, with and without diabetes.